CORRECTED COPY

MATERIALS LICENSE

Amendment No. 07

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Tolfree Memorial Hospital	In accordance with application dated March 12, 1985 3. License number 21-18892-01 is amended in its entirety to read as follows:
2. 335 East Houghton Avenue West Branch, MI 48661	4. Expiration date: June 30, 1990
	5. Docket or Reference No.: 030-17321

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B
C. Iodine-131	C. Any iodide that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State regulations.	C. 250 millicuries

1/1 COPY 2

MLBP

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 21-18892-01

Docket or Reference number 030-17321

CORRECTED COPY

Amendment No. 07

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
D. Xenon-133	D. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	D. 300 millicuries
E. Americium 241	E. Sealed source Amersham/ Searle Model No. AMC.24	E. 14 millicuries

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. For treatment of hyperthyroidism, cardiac dysfunction, or thyroid carcinoma.

D. Blood flow studies. Pulmonary function studies.

E. To be used in Searle Analytic Anatomical Marker Model SS-10244.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 335 East Houghton Avenue, West Branch, Michigan.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 21-18892-01

Docket or Reference number 030-17321

CORRECTED COPY

Amendment No. 07

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Paul W. Rowe, M.D.	Groups I, II and III Iodine-131 for the treatment of hyperthyroidism, cardiac dysfunction or thyroid carcinoma Xenon-133 Americium-241 anatomical marker
Harold Blumenstein, M.D.	Groups I, II and III Iodine-131 for the treatment of hyperthyroidism, cardiac dysfunction or thyroid carcinoma Xenon-133 Americium-241 anatomical marker
James Fenton, M.D.	Groups I, II and III Iodine-131 for the treatment of hyperthyroidism Xenon-133 Americium-241 anatomical marker
Paul J. Hettle, M.D.	Groups I, II and III Iodine-131 for the treatment of hyperthyroidism Xenon-133 Americium-241 anatomical marker
Tyre K. Jones, III, M.D.	Groups I, II and III Xenon-133 Americium-241 anatomical marker
George F. Ascherl, M.D.	Groups I, II and III Xenon-133 Americium-241 anatomical marker
Stephen M. Ascherl, M.D.	Groups I, II and III Xenon-133 Americium-241 anatomical marker

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

(a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 21-18892-01

Docket or Reference number 030-17321

CORRECTED COPY

Amendment No. 07

(b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

(c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

15. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated March 12, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed
By J.R. Madera
Materials Licensing Section, Region III

Date July 19, 1985

COPY